PANS
Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects
Sponsor study identifier
Secondary identifiers
OTHER · Belgian Study Registration Number
observational
106
1 country
3
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2017
Actual (reported)Study Completion
February 2017
Actual (reported)Previous research has suggested central nervous system inflammatory activity to be critically involved in disease development and progression in schizophrenia, with a complex interplay of inflammatory mechanisms leading to the development of brain abnormalities and medical symptoms related to schizophrenia. However, the mutual interactions of different inflammatory pathways and their relation to disease course have not been sufficiently studied. This study therefore aims to explore the interaction of neuroinflammatory mechanisms in patients with schizophrenia and to assess whether the inflammatory activity in schizophrenia is state-dependent and occurs mainly during psychotic episodes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
December 9, 2013
Actual (reported)December 12, 2013
Actual (reported)February 2017
Actual (reported)February 2017
Actual (reported)Regional VT of [18F]PBR111
Regional distribution volume in tissue (VT) of 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (PBR111) labelled with fluorine-18 (18F) in schizophrenia patients and age- , gender-, and translocator protein (TSPO) binding profile- matched healthy controls
2 years
Peripheral markers
2 years
Healthy age- and sex-matched controls
Young schizophrenia patients 18-40y
\[18F\]-PBR111 radioligand to assess binding to TSPO
Cognitive and psychomotor tasks on digitizing tablet
Young schizophrenia patients admitted to psychiatric hospital for acute relapse or first-episode of psychosis
Psychiatrisch Ziekenhuis Broeders Alexianen
Boechout, Antwerpen, 2530, Belgium
Psychiatrisch Ziekenhuis St Norbertus
Duffel, Antwerpen, 2570, Belgium
Psychiatrisch Ziekenhuis Sint-Amedeus
Mortsel, Antwerp, 2640, Belgium
Plasma samples
Bernard Sabbe, MD PhD
Universiteit Antwerpen
106 participants (actual enrollment reported by the registry).
First Submitted
December 9, 2013
First Posted
December 12, 2013
Study Start
November 2013
Date type not reportedThis date has not been verified as actual or estimated.
Multi-site Communication Deficits in Schizophrenia
Blood sampling for peripheral inflammatory and neurotoxicity markers
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
February 2017
Actual (reported)Study Completion
February 2017
Actual (reported)Last Updated
August 31, 2017
Record last verified: 2017-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: